This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Following are the Emerging Science abstracts that were presented as part of the 2020 American Academy of Neurology Science Highlights virtual platform. Abstracts qualify for Emerging Science presentations by having key aspects of research conducted after the October 21 abstract submission deadline and must be new and of sufficient scientific importance to warrant expedited presentation and publication.
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Efficacy and safety results from part 2 MOXIe: A randomized, double-blind, placebo-controlled trial of omaveloxolone in Friedreich ataxia
- Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington disease: The prospective HD-CSF study
- EMERGE and ENGAGE topline results: Phase 3 studies of aducanumab in early Alzheimer disease
- NILO-PD: A phase 2A study of nilotinib in patients with advanced Parkinson disease: Final study results
- Increased amygdala volume and functional connectivity with large-scale brain networks in chronic migraine: Associations with clinical and affective measures
- Efficacy and safety of 3 different dosages of IVIg (Panzyga) in patients with CIDP (ProCID study)
- The HEALEY ALS platform trial
- Efficacy and safety of AXS-07 for the acute treatment of migraine: Results from the MOMENTUM (Maximizing Outcomes in Treating Acute Migraine) phase 3 randomized, double-blind, active- and placebo-controlled study
- TERIKIDS study: Teriflunomide efficacy and safety in pediatric patients with relapsing forms of MS
- A randomized, double-blind trial of amantadine, modafinil, and methylphenidate for the treatment of multiple sclerosis fatigue
- Safety and efficacy of tilavonemab (ABBV-8E12), a humanized anti-tau monoclonal antibody, for the treatment of progressive supranuclear palsy: Results from a phase 2, randomized, placebo-controlled, multicenter study
- Galcanezumab in patients with treatment-resistant migraine: Results from the open-label phase of the CONQUER phase 3 trial
- Info & Disclosures
